CLAIMS

1. A polypeptide dimer having a high content of sialic acid, comprising:

two monomers, each of which contains an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIα-ECD),

wherein the extracellular domain of the alpha subunit of the IgE Fc receptor has the amino acid sequence of SEQ ID NO: 1,

wherein each of the monomers contains an Fc region, and

the Fc region and the FcεRIα-ECD are linked via a hinge,

wherein the hinge is Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 17) or Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 18),

Xaa1 and Xaa3 are Gly, and

Xaa2 and Xaa4 are Gly or Ser,

wherein the molar ratio of sialic acid/polypeptide dimer in the polypeptide dimer is 12 to 25.

2. The polypeptide dimer having a high content of sialic acid according to claim 1, wherein the Fc region has the amino acid sequence of SEQ ID NO: 2.

3. The polypeptide dimer having a high content of sialic acid according to claim 1, wherein the sialic acid is N-acetylneuraminic acid.

4. The polypeptide dimer having a high content of sialic acid according to claim 1, wherein the hinge has any one amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4.

5. A pharmaceutical composition for use in treating or preventing an IgE-mediated allergic disease, comprising a polypeptide dimer having a high content of sialic acid according to any of claims 1 to 4.

6. The pharmaceutical composition for use in treating or preventing an IgE-mediated allergic disease according to claim 5, wherein the pharmaceutical composition is for subcutaneous injection.

7. The pharmaceutical composition for use in treating or preventing an allergic disease according to claim 5, wherein the IgE-mediated allergic disease is any one selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis.

8. A transdermal patch comprising the pharmaceutical composition of claim 5.

9. A topical patch comprising the pharmaceutical composition of claim 5.

10. A food composition for ameliorating or alleviating an IgE-mediated allergic symptom, comprising a polypeptide dimer having a high content of sialic acid according to any of claims 1 to 4.

11. A use of the polypeptide dimer having a high content of sialic acid according to any of claims 1 to 4 in the preparation of a medicament for preventing or treating an IgE-mediated allergic disease.